Gynaecological Cancers in India: The Importance of Early Attention and Timely Care

Gynaecological Cancers refer to cancers that develop in the female reproductive system. It is no longer a rare group of diseases. They include cancers of the cervix, ovaries, uterus, vulva and, in some cases, certain pregnancy-related tumours. These cancers have emerged as a major women's health concern in India.

According to GLOBOCAN and the Indian Council of Medical Research's National Cancer Registry Programme, cervical, ovarian, and uterine cancers together account for a substantial share of new cancer diagnoses among Indian women each year - with cervical cancer alone accounting for tens of thousands of new cases and a large share of avoidable cancer deaths.

Common Gynaecological Cancers in Indian Women

Among Indian women, cervical cancer remains one of the biggest concerns, followed by ovarian cancer, which has increasingly become a common gynaecological cancer. While uterine cancer is less common than in some Western countries, it still contributes significantly to the overall disease burden.

Understanding the main gynaecological cancers helps women recognise the specific symptoms and risk factors associated with each.

Symptoms That Should Not Be Ignored

One of the major challenges faced by oncologists in India is that many women ignore early warning signs or delay seeking medical attention.

These cancers may first present with symptoms such as:

• Abnormal bleeding, especially around or after menopause
• Unusual vaginal discharge
• Pelvic pain
• A lump or swelling in the lower abdomen
• A feeling of fullness or swelling in the pelvic region

Why Early Consultation Matters

Early consultation and timely screening can make a real difference. Lack of awareness and limited access to screening remain important reasons for delayed diagnosis in many cases.

For women, this serves as an important reminder not to normalise abnormal symptoms. If there is unusual bleeding, discharge, pelvic pain or abdominal swelling, it is wise to seek specialist advice without delay.

The Importance of Timely Evaluation

Timely evaluation can help:

• Detect problems at an earlier stage
• Guide treatment decisions sooner
• Improve the chances of better outcomes
• Support more effective long-term management

Seeking medical attention early can make a meaningful difference in the diagnosis and treatment of gynaecological cancers.

Screening and Early Detection: What Actually Works  

Screening looks for signs of cancer - or the changes that precede it - in women who feel well. What is available depends on the cancer:

Cervical Cancer (screening works very well)  

• A Pap smear test (from age 21, or as advised locally) every 3 years, or an HPV DNA test every 5 years, or the two combined - up to age 65. Your gynaecologist can advise the right schedule for you.
• Cervical screening detects pre-cancerous changes so they can be treated before they become cancer. Vaccinated women still need to be screened.

Endometrial (Uterine) Cancer (symptom-triggered evaluation)  

• There is no routine screening test, but the symptom - postmenopausal bleeding - is very often noticed early. Any bleeding after menopause should prompt a gynaecologist visit, usually with a pelvic ultrasound and, if needed, an endometrial biopsy.

Ovarian Cancer (why symptom-awareness matters)  

• There is currently no reliable general screening test for ovarian cancer in average-risk women. Transvaginal ultrasound and the blood test CA-125 have not been shown to reduce ovarian-cancer deaths in general screening, and can produce false results.
• This is why symptom awareness is the mainstay: persistent bloating, feeling full quickly, and abdominal or pelvic discomfort lasting more than a few weeks should be checked.
• Women with a strong family history or a known BRCA1/2 or Lynch mutation should be under specialist care and may be offered risk-reducing options.

Read More about Ovarian Cancer in Young Females

Risk Factors for Gynaecological Cancers  

• Persistent HPV infection (cervical and vulvar cancers)
• Tobacco use, including bidis and smokeless tobacco
• Obesity and diabetes (mainly endometrial cancer)
• Family history and inherited syndromes - BRCA1 and BRCA2 mutations (breast and ovarian), and Lynch syndrome (endometrial, ovarian, colorectal). A strong family history warrants referral for genetic counselling.
• Long-term unopposed oestrogen exposure (endometrial cancer)
• Late menopause, early menarche, and nulliparity (fewer full-term pregnancies)
• Older age (all gynaecological cancers)
• Weakened immunity (for example, HIV)

Recommended Read: Types of Cancer in Women

Prevention: Practical Steps for Every Woman  

• HPV vaccination: for girls (and increasingly boys) as recommended for their age; India's Cervavac is now available.
• Attend cervical screening at the recommended intervals, even if you have had the HPV vaccine.
• Do not normalise unusual bleeding, discharge, or persistent pelvic symptoms - seek review.
• Do not use tobacco in any form; limit alcohol.
• Maintain a healthy weight, be physically active, and manage diabetes and blood pressure well.
• Discuss family history with your doctor. If several close relatives have had breast, ovarian, uterine, or colorectal cancer, or if there is a known BRCA or Lynch mutation in the family, ask about genetic counselling.

Disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice. Any woman with new or persistent gynaecological symptoms - particularly bleeding after menopause - should see a qualified doctor or gynaecologist promptly.

Frequently Asked Questions  

1. What are the most common gynaecological cancers in India?  

Cervical cancer is the most common, followed by ovarian and uterine (endometrial) cancers. Vulvar cancer and gestational trophoblastic disease are less common.

2. Can gynaecological cancers be prevented?  

Cervical cancer is largely preventable with HPV vaccination and regular screening. For other gynae cancers, staying alert to symptoms, avoiding tobacco, maintaining a healthy weight, and - where a strong family history exists - having genetic counselling all help.

3. Is any postmenopausal bleeding serious?  

Yes - any bleeding after menopause should be checked by a doctor, even if it is a small amount and only happens once. Many causes turn out to be benign, but endometrial cancer must be ruled out.

4. Is there a screening test for ovarian cancer?  

Not for average-risk women. Ultrasound and CA-125 blood tests have not been shown to reduce ovarian-cancer deaths in general screening. This is why symptom awareness - persistent bloating, early fullness, pelvic pain lasting more than a few weeks - is so important. Women with a strong family history or known BRCA / Lynch mutations should be under specialist care.

5. At what age should HPV vaccination be given?  

HPV vaccination is most effective when given before exposure to HPV - typically age 9–14 - but can also be given later, up to around age 26 (and, in some situations, older). Ask your doctor about the right schedule and vaccine for you or your daughter.

6. Do I still need Pap smears if I have had the HPV vaccine?  

Yes. The vaccine protects against most, but not all, high-risk HPV types. Regular cervical screening remains essential even for vaccinated women.

7. When should I see a gynaecologist urgently?  

For any bleeding after menopause, persistent bloating or abdominal swelling lasting more than about three weeks, unexplained weight loss, or a new pelvic lump. These may have benign causes, but they need to be checked. 

References 

World Health Organization.Cervical cancer. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer

World Health Organization.Global strategy to accelerate the elimination of cervical cancer as a public health problem. https://www.who.int/publications/i/item/9789240014107

American College of Obstetricians and Gynecologists. Cervical cancer screening. https://www.acog.org/womens-health/faqs/cervical-cancer-screening

Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) randomized controlled trial. JAMA, 305(22), 2295–2303. https://doi.org/10.1001/jama.2011.766